psychiatrist

This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Article

Overview of Psychiatric Disorders and the Role of Newer Antidepressants

Dennis S. Charney, MD; Dale R. Grothe, PharmD, BCPP; and Sherry L. Smith, PharmD, BCPP; Kathleen T. Brady, MD, PhD, and Juliana Kaltsounis-Puckett, PharmD, BCPP; Clinton W. Wright, PharmD, BCPP; Lyle K. Laird, PharmD, BCPP; and A. John Rush, MD

Published: January 1, 2002

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

4 The Course of Major Depressive Disorder. Dennis S. Charney, M.D.; Dale R. Grothe, Pharm.D., B.C.P.P.; and Sherry L. Smith, Pharm.D., B.C.P.P. From the Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Md. (Dr. Charney); Medical Education Development Services, Comprehensive Neuroscience, Inc., Chevy Chase, Md. (Dr. Grothe); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Marietta, Ga. (Dr. Smith). Reprint requests to: Dennis S. Charney, M.D., Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 9000 Rockville Pike, Bldg. 10, Room 4N222, Bethesda, MD 20892 (e-mail: [email protected]). 5 Major Depressive Disorder With Anxiety Symptoms or Sleep Disturbance. Kathleen T. Brady, M.D., Ph.D., and Juliana Kaltsounis-Puckett, Pharm.D., B.C.P.P. From the Department of Psychiatry, Medical University of South Carolina, Charleston (Dr. Brady); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Richmond, Va. (Dr. Kaltsounis-Puckett). Reprint requests to: Kathleen T. Brady, M.D., Ph.D., Department of Psychiatry, Medical University of South Carolina, 67 President St., P.O. Box 250861, Charleston, SC 29425 (e-mail: [email protected]). 7 Antidepressant Selection: Focus on Nefazodone. Clinton W. Wright, Pharm.D., B.C.P.P.; Lyle K. Laird, Pharm.D., B.C.P.P.; and A. John Rush, M.D. From the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, San Antonio, Tex. (Dr. Wright); the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, Denver, Colo. (Dr. Laird); the School of Pharmacy, University of Colorado Health Sciences Center, Denver (Dr. Laird); and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Dr. Rush). Reprint requests to: A. John Rush, M.D., Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9086 (e-mail: [email protected]


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: